Home  ›  Ldl Cholesterol Reading of 76 in 77 Year Old Male

Ldl Cholesterol Reading of 76 in 77 Year Old Male

Written By Sunday, March 6, 2022 Add Comment Edit

One of the five major groups of lipoprotein

LDL has been associated with the progression of atherosclerosis and blockage of the artery lumen, because it can carry cholesterol into smaller vessels. But LDL is also essential for conveying lipids that keep the human torso alive, including in those pocket-sized vessels.

Low-density lipoprotein (LDL) is ane of the five major groups of lipoprotein which transport all fat molecules around the body in the extracellular h2o.[one] These groups, from least dumbo to most dense, are chylomicrons (aka ULDL past the overall density naming convention), very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), depression-density lipoprotein (LDL) and high-density lipoprotein (HDL). LDL delivers fat molecules to cells. LDL is involved in atherosclerosis, a process in which it is oxidized within the walls of arteries.

Overview [edit]

Lipoproteins transfer lipids (fats) around the body in the extracellular fluid, making fats bachelor to trunk cells for receptor-mediated endocytosis.[2] [3] Lipoproteins are circuitous particles composed of multiple proteins, typically eighty–100 proteins per particle (organized past a single apolipoprotein B for LDL and the larger particles). A single LDL particle is about 220–275 angstroms in diameter, typically transporting three,000 to 6,000 fat molecules per particle, and varying in size co-ordinate to the number and mix of fat molecules contained within.[iv] The lipids carried include all fat molecules with cholesterol, phospholipids, and triglycerides dominant; amounts of each vary considerably.[ citation needed ]

The common clinical interpretation of blood lipid levels is that high LDL is associated with increased risk of cardiovascular diseases.[5]

Biochemistry [edit]

Structure [edit]

Each native LDL particle enables emulsification, i.e. surrounding the fatty acids beingness carried, enabling these fats to move around the body within the h2o exterior cells. Each particle contains a single apolipoprotein B-100 molecule (Apo B-100, a protein that has 4536 amino acid residues and a mass of 514 kDa), along with lxxx to 100 boosted ancillary proteins. Each LDL has a highly hydrophobic cadre consisting of polyunsaturated fatty acid known as linoleate and hundreds to thousands (about 1500 ordinarily cited as an average) of esterified and unesterified cholesterol molecules. This cadre besides carries varying numbers of triglycerides and other fats and is surrounded by a beat of phospholipids and unesterified cholesterol, as well every bit the single copy of Apo B-100. LDL particles are approximately 22 nm (0.00000087 in.) to 27.5 nm in diameter and have a mass of about iii 1000000 daltons.[six] Since LDL particles contain a variable and irresolute number of fat acrid molecules, there is a distribution of LDL particle mass and size.[4] Determining the structure of LDL has been a tough task because of its heterogeneous structure. The structure of LDL at homo body temperature in native condition, with a resolution of about 16 Angstroms using cryogenic electron microscopy, has been recently described.[7]

Physiology [edit]

LDL particles are formed when triglycerides are removed from VLDL past the lipoprotein lipase enzyme (LPL) and they become smaller and denser (i.e. fewer fatty molecules with aforementioned protein transport beat out), containing a higher proportion of cholesterol esters.[ citation needed ]

Transport into the cell [edit]

When a cell requires boosted cholesterol (beyond its current internal HMGCoA production pathway), it synthesizes the necessary LDL receptors every bit well as PCSK9, a proprotein convertase that marks the LDL receptor for degradation.[eight] LDL receptors are inserted into the plasma membrane and diffuse freely until they associate with clathrin-coated pits. When LDL receptors bind LDL particles in the bloodstream, the clathrin-coated pits are endocytosed into the cell.

Vesicles containing LDL receptors leap to LDL are delivered to the endosome. In the presence of low pH, such as that found in the endosome, LDL receptors undergo a conformation change, releasing LDL. LDL is so shipped to the lysosome, where cholesterol esters in the LDL are hydrolysed. LDL receptors are typically returned to the plasma membrane, where they echo this cycle. If LDL receptors bind to PCSK9, however, transport of LDL receptors is redirected to the lysosome, where they are degraded.[nine]

Office in the innate immune system [edit]

LDL interfere with the quorum sensing system that upregulates genes required for invasive Staphylococcus aureus infection. The mechanism of antagonism entails binding apolipoprotein B to a Southward. aureus autoinducer pheromone, preventing signaling through its receptor. Mice deficient in apolipoprotein B are more susceptible to invasive bacterial infection.[ten]

LDL size patterns [edit]

LDL tin can be grouped based on its size: large low density LDL particles are described as pattern A, and small loftier density LDL particles are pattern B. Design B has been associated by some with a college run a risk for coronary heart disease.[eleven] : 1–x This is thought to be considering the smaller particles are more easily able to penetrate the endothelium of arterial walls. Design I, for intermediate, indicates that most LDL particles are very close in size to the normal gaps in the endothelium (26 nm). Co-ordinate to 1 report, sizes 19.0–xx.5 nm were designated equally pattern B and LDL sizes 20.6–22 nm were designated as design A.[12] Other studies accept shown no such correlation at all.[xiii]

Some evidence suggests the correlation between Pattern B and coronary middle disease is stronger than the correspondence betwixt the LDL number measured in the standard lipid contour exam. Tests to measure out these LDL subtype patterns have been more expensive and not widely available, so the common lipid profile test is used more than often.[11]

At that place has also been noted a correspondence betwixt higher triglyceride levels and college levels of smaller, denser LDL particles and alternately lower triglyceride levels and higher levels of the larger, less dense ("buoyant") LDL.[14] [15]

With continued research, decreasing price, greater availability and wider acceptance of other lipoprotein subclass analysis assay methods, including NMR spectroscopy, research studies have continued to show a stronger correlation betwixt human being clinically obvious cardiovascular events and quantitatively measured particle concentrations.[sixteen]

Oxidized LDL [edit]

Oxidized LDL is a general term for LDL particles with oxidatively modified structural components. Every bit a event from free radical attack, both lipid and poly peptide parts of LDL can exist oxidized in the vascular wall. Besides the oxidative reactions taking place in vascular wall, oxidized lipids in LDL can likewise be derived from oxidized dietary lipids.[17] [18] Oxidized LDL is known to associate with the development of atherosclerosis, and it is therefore widely studied as a potential risk factor of cardiovascular diseases.[19] Atherogenicity of oxidized LDL has been explained by lack of recognition of oxidation-modified LDL structures by the LDL receptors, preventing the normal metabolism of LDL particles and leading eventually to development of atherosclerotic plaques.[xix] Of the lipid fabric independent in LDL, various lipid oxidation products are known as the ultimate atherogenic species.[20] Acting as a transporter of these injurious molecules is another mechanism by which LDL tin can increment the risk of atherosclerosis.[18] [21]

Testing [edit]

Blood tests commonly study LDL-C: the corporeality of cholesterol which is estimated to be independent with LDL particles, on average, using a formula, the Friedewald equation. In clinical context, mathematically calculated estimates of LDL-C are normally used as an approximate of how much low density lipoproteins are driving progression of atherosclerosis. The trouble with this approach is that LDL-C values are usually discordant with both direct measurements of LDL particles and actual rates of atherosclerosis progression.

Directly LDL measurements are also available and better reveal private problems but are less often promoted or washed due to slightly higher costs and being available from only a couple of laboratories in the Usa. In 2008, the ADA and ACC recognized straight LDL particle measurement by NMR as superior for assessing individual risk of cardiovascular events.[22]

Estimation of LDL particles via cholesterol content [edit]

Chemical measures of lipid concentration have long been the virtually-used clinical measurement, not because they have the best correlation with individual effect, but because these lab methods are less expensive and more widely available.

The lipid profile does not measure out LDL particles. It only estimates them using the Friedewald equation[15] [23] by subtracting the corporeality of cholesterol associated with other particles, such equally HDL and VLDL, assuming a prolonged fasting state, etc.:

L ≈ C − H − thousand T {\displaystyle 50\approx C-H-kT}
where H is HDL cholesterol, L is LDL cholesterol, C is full cholesterol, T are triglycerides, and one thousand is 0.20 if the quantities are measured in mg/dl and 0.45 if in mmol/l.

There are limitations to this method, most notably that samples must be obtained after a 12 to fourteen h fast and that LDL-C cannot be calculated if plasma triglyceride is >four.52 mmol/L (400 mg/dL). Fifty-fifty at triglyceride levels 2.5 to 4.5 mmol/Fifty, this formula is considered inaccurate.[24] If both total cholesterol and triglyceride levels are elevated then a modified formula, with quantities in mg/dl, may exist used

50 = C − H − 0.xvi T {\displaystyle L=C-H-0.16T}

This formula provides an approximation with off-white accuracy for well-nigh people, assuming the blood was drawn after fasting for about xiv hours or longer, simply does not reveal the actual LDL particle concentration considering the percentage of fat molecules within the LDL particles which are cholesterol varies, equally much as viii:1 variation.

However, the concentration of LDL particles, and to a lesser extent their size, has a stronger and consistent correlation with individual clinical upshot than the corporeality of cholesterol inside LDL particles, even if the LDL-C estimation is approximately correct. There is increasing testify and recognition of the value of more targeted and accurate measurements of LDL particles. Specifically, LDL particle number (concentration), and to a lesser extent size, take shown slightly stronger correlations with atherosclerotic progression and cardiovascular events than obtained using chemical measures of the amount of cholesterol carried by the LDL particles.[25] It is possible that the LDL cholesterol concentration can exist low, yet LDL particle number loftier and cardiovascular events rates are high. Correspondingly, it is possible that LDL cholesterol concentration tin can be relatively high, yet LDL particle number depression and cardiovascular events are also low.

Normal ranges [edit]

In the US, the American Center Association, NIH, and NCEP provide a ready of guidelines for fasting LDL-Cholesterol levels, estimated or measured, and take chances for heart illness. Every bit of most 2005, these guidelines were:[26] [27] [28]

Level mg/dL Level mmol/L Interpretation
25 to <50 <1.3 Optimal LDL cholesterol, levels in healthy young children before onset of atherosclerotic plaque in heart artery walls
<70 <1.viii Optimal LDL cholesterol, corresponding to lower rates of progression, promoted equally a target selection for those known to clearly have avant-garde symptomatic cardiovascular disease
<100 <ii.6 Optimal LDL cholesterol, corresponding to lower, but not aught, rates for symptomatic cardiovascular disease events
100 to 129 2.6 to iii.3 Most optimal LDL level, corresponding to college rates for developing symptomatic cardiovascular disease events
130 to 159 3.3 to iv.1 Borderline high LDL level, corresponding to even higher rates for developing symptomatic cardiovascular illness events
160 to 199 iv.1 to 4.9 High LDL level, respective to much higher rates for developing symptomatic cardiovascular disease events
>200 >iv.9 Very loftier LDL level, respective to highest increased rates of symptomatic cardiovascular disease events

Over time, with more than clinical research, these recommended levels continue being reduced considering LDL reduction, including to abnormally depression levels, was the well-nigh effective strategy for reducing cardiovascular death rates in one large double bullheaded, randomized clinical trial of men with hypercholesterolemia;[29] far more effective than coronary angioplasty/stenting or bypass surgery.[30]

For example, for people with known atherosclerosis diseases, the 2004 updated American Heart Association, NIH and NCEP recommendations are for LDL levels to exist lowered to less than 70 mg/dL, unspecified how much lower. This low level of less than 70 mg/dL (higher than Tim Russert'south value shortly prior to his heart assail) was recommended for master prevention of 'very-loftier risk patients' and in secondary prevention as a 'reasonable further reduction'. Lack of testify for such a recommendation is discussed in an article in the Annals of Internal Medicine.[31] Statin drugs involved in such clinical trials have numerous physiological furnishings beyond simply the reduction of LDL levels.

It has been estimated from the results of multiple man pharmacologic LDL lowering trials[32] that LDL should be lowered to below 30 to reduce cardiovascular effect rates to almost nix. For reference, from longitudinal population studies following progression of atherosclerosis-related behaviors from early on childhood into machismo,[33] [ better source needed ] the usual LDL in childhood, before the development of fatty streaks, is well-nigh 35 mg/dL. Nonetheless, all the above values refer to chemical measures of lipid/cholesterol concentration within LDL, non measured depression-density lipoprotein concentrations, the accurate approach.

A study was conducted measuring the effects of guideline changes on LDL cholesterol reporting and control for diabetes visits in the US from 1995 to 2004. Information technology was constitute that although LDL cholesterol reporting and command for diabetes and coronary heart affliction visits improved continuously between 1995 and 2004,[ citation needed ] neither the 1998 ADA guidelines nor the 2001 ATP III guidelines increased LDL cholesterol control for diabetes relative to coronary centre disease.[34]

Straight measurement of LDL particle concentrations [edit]

There are several competing methods for measurement of lipoprotein particle concentrations and size. The evidence is that the NMR methodology (adult, automated & profoundly reduced in costs while improving accuracy as pioneered by Jim Otvos and associates) results in a 22-25% reduction in cardiovascular events inside one yr,[35] contrary to the longstanding claims past many in the medical industry that the superiority over existing methods was weak, even by statements of some proponents.[36]

Since the later 1990s, because of the development of NMR measurements, it has been possible to clinically measure out lipoprotein particles at lower cost [under $80 United states (including aircraft) & is decreasing; versus the previous costs of >$400 to >$five,000] and higher accuracy. There are 2 other assays for LDL particles, nevertheless, similar LDL-C, most only estimate LDL particle concentrations.

Direct LDL particle measurement by NMR was mentioned by the ADA and ACC, in a 28 March 2008 joint consensus statement,[37] as having advantages for predicting private risk of atherosclerosis disease events, just the argument noted that the test is less widely available, is more than expensive [about $13.00 US (2015 without insurance coverage) from some labs which use the Vantera Analyzer[38]]. Debate continues that it is "...unclear whether LDL particle size measurements add together value to measurement of LDL-particle concentration", though outcomes have always tracked LDL particle, not LDL-C, concentrations.

Using NMR, as pioneered by researcher Jim Otvos and the Due north Carolina State University academic inquiry spin-off company LipoScience, the total LDL particle concentrations, in nmol/L plasma, are typically subdivided by percentiles referenced to the five,382 men and women, not on any lipid medications, who are participating in the MESA trial.[39]

Optimal ranges [edit]

The LDL particle concentrations are typically categorized by percentiles, <20%, 20–fifty%, 50th–80th%, 80th–95% and >95% groups of the people participating and being tracked in the MESA trial, a medical research written report sponsored past the United states of america National Middle, Lung, and Claret Institute.

MESA Percentile LDL particles nmol/L Interpretation
0–20% <1,000 Those with everyman rate of cardiovascular disease events & low (optimal) LDL particle concentration
twenty–fifty% i,000–1,299 Those with moderate charge per unit of cardiovascular disease events & moderate LDL particle concentration
50–eighty% 1,300–one,599 Those with Borderline-High rate of cardiovascular affliction events & higher LDL particle concentration
89–95% one,600–two,000 Those with High rate of cardiovascular disease events and fifty-fifty college LDL particle concentration
>95% >2,000 Those with very high rate of cardiovascular disease events and highest LDL particle concentration

The lowest incidence of atherosclerotic events over fourth dimension occurs within the <xx% group, with increased rates for the college groups. Multiple other measures, including particle sizes, small-scale LDL particle concentrations, big total and HDL particle concentrations, along with estimations of insulin resistance pattern and standard cholesterol lipid measurements (for comparing of the plasma information with the estimation methods discussed above) are also routinely provided.

Lowering LDL-cholesterol [edit]

Markers indicating a need for LDL-C Reduction

(Per 2004 United States Government Minimum Guidelines[40] [41])

If the patient'due south cardiac chance is... then the patient should consider LDL-C reduction if the count in mg/dL is over... and LDL-C reduction is indicated if the count in mg/dL is over...
Loftier, meaning a 20% or greater risk of heart attack inside 10 years, or an extreme risk cistron seventy[42] 100[42]
moderately high, pregnant a 10-20% risk of heart attack within 10 years and more than two centre attack adventure factors 100[42] 130[42]
moderate, pregnant a ten% take chances of heart attack within 10 years and more than 2 heart set on take chances factors 130[42] 160[42]
depression, pregnant less than 10% chance of heart assail within 10 years and 1 or 0 heart assault risk factors 160[42] 190[42]

The mevalonate pathway serves equally the basis for the biosynthesis of many molecules, including cholesterol. The enzyme iii-hydroxy-three-methylglutaryl coenzyme A reductase (HMG CoA reductase) is an essential component and performs the first of 37 steps within the cholesterol production pathway, and is present in every animal cell.

LDL-C is not a measurement of actual LDL particles. LDL-C is merely an estimate (non measured from the private's blood sample) of how much cholesterol is being transported by all LDL particles, which is either a smaller concentration of large particles or a high concentration of minor particles. LDL particles acquit many fatty molecules (typically 3,000 to six,000 fatty molecules per LDL particle); this includes cholesterol, triglycerides, phospholipids and others. Thus even if the hundreds to thousands of cholesterol molecules within an average LDL particle were measured, this does non reflect the other fat molecules or even the number of LDL particles.

Pharmaceutical [edit]

  • PCSK9 inhibitors, in clinical trials, by several companies, are more effective for LDL reduction than the statins, including statins solitary at loftier dose (though not necessarily the combination of statins plus ezetimibe).
  • Statins reduce high levels of LDL particles by inhibiting the enzyme HMG-CoA reductase in cells, the charge per unit-limiting step of cholesterol synthesis. To compensate for the decreased cholesterol availability, synthesis of LDL receptors (including hepatic) is increased, resulting in an increased clearance of LDL particles from the extracellular h2o, including of the claret.
  • Ezetimibe reduces intestinal absorption of cholesterol, thus can reduce LDL particle concentrations when combined with statins.[43]
  • Niacin (B3), lowers LDL by selectively inhibiting hepatic diacylglycerol acyltransferase 2, reducing triglyceride synthesis and VLDL secretion through a receptor HM74[44] and HM74A or GPR109A.[45]
  • Several CETP inhibitors have been researched to improve HDL concentrations, but and so far, despite dramatically increasing HDL-C, have non had a consistent track tape in reducing atherosclerosis illness events. Some take increased bloodshed rates compared with placebo.
  • Clofibrate is effective at lowering cholesterol levels, merely has been associated with significantly increased cancer and stroke mortality, despite lowered cholesterol levels.[46] Other, more recently adult and tested fibrates, e.m. fenofibric acid[47] have had a meliorate track tape and are primarily promoted for lowering VLDL particles (triglycerides), not LDL particles, notwithstanding can aid some in combination with other strategies.
  • Some Tocotrienols, especially delta- and gamma-tocotrienols, are being promoted equally statin alternative non-prescription agents to treat high cholesterol, having been shown in vitro to have an effect. In item, gamma-tocotrienol appears to exist another HMG-CoA reductase inhibitor, and tin reduce cholesterol production.[48] Equally with statins, this decrease in intra-hepatic (liver) LDL levels may induce hepatic LDL receptor up-regulation, also decreasing plasma LDL levels. As always, a primal outcome is how benefits and complications of such agents compare with statins—molecular tools that take been analyzed in large numbers of homo research and clinical trials since the mid-1970s.
  • Phytosterols are widely recognized as having a proven LDL cholesterol lowering efficacy,[49] although no scientifically proven benign consequence on cardiovascular disease (CVD) or overall mortality exists.[50] Current supplemental guidelines for reducing LDL recommend doses of phytosterols in the ane.half-dozen-3.0 grams per day range (Health Canada, EFSA, ATP III, FDA) with a recent meta-analysis demonstrating an 8.8% reduction in LDL-cholesterol at a mean dose of 2.fifteen gram per day.[51]

Gene editing [edit]

In 2021, scientists demonstrated that CRISPR gene editing can decrease claret levels of LDL cholesterol in vivo in Macaca fascicularis monkeys for months by sixty % via knockdown of PCSK9 in the liver.[52] [53]

Lifestyle [edit]

  • The nigh effective approach has been minimizing fatty stores located inside the abdominal cavity (visceral body fat) in improver to minimizing full body fat.[ citation needed ] Visceral fat, which is more metabolically active than subcutaneous fatty, has been plant to produce many enzymatic signals, e.g. resistin,[ citation needed ] which increase insulin resistance and circulating VLDL particle concentrations, thus both increasing LDL particle concentrations and accelerating the development of diabetes mellitus.

See also [edit]

  • Catechin
  • Cholesterol
  • Lysosomal acid lipase deficiency
  • Cholesteryl ester storage disease
  • Coenzyme Q10
  • Flavonoid
  • Glutathione
  • Health effects of tea
  • High density lipoprotein
  • LDL receptor
  • Lipid contour
  • Lipoprotein(a)
  • Lipoprotein-X
  • Melatonin
  • Polyphenol antioxidant
  • Saturated fat
  • Stanol ester
  • Sterol ester
  • Triglyceride
  • Vitamin A
  • Vitamin C
  • Vitamin Eastward

Notes and references [edit]

  1. ^ "LDL and HDL: Bad and Good Cholesterol". Centers for Disease Control and Prevention. CDC. Retrieved 11 September 2017.
  2. ^ Dashti M, Kulik W, Hoek F, Veerman EC, Peppelenbosch MP, Rezaee F (2011). "A phospholipidomic analysis of all divers human plasma lipoproteins". Sci. Rep. 1 (139): 139. Bibcode:2011NatSR...1E.139D. doi:10.1038/srep00139. PMC3216620. PMID 22355656.
  3. ^ Dashty M, Motazacker MM, Levels J, de Vries M, Mahmoudi M, Peppelenbosch MP, Rezaee F (2014). "Proteome of human being plasma very low-density lipoprotein and low-density lipoprotein exhibits a link with coagulation and lipid metabolism". Thromb. Haemost. 111 (3): 518–530. doi:ten.1160/TH13-02-0178. PMID 24500811.
  4. ^ a b Segrest JP, Jones MK, De Loof H, Dashti North (September 2001). "Structure of apolipoprotein B-100 in low density lipoproteins". Journal of Lipid Research. 42 (nine): 1346–67. doi:10.1016/S0022-2275(20)30267-4. PMID 11518754.
  5. ^ Carson, Jo Ann S.; Lichtenstein, Alice H.; Anderson, Cheryl A.M.; Appel, Lawrence J.; Kris-Etherton, Penny Grand.; Meyer, Katie A.; Petersen, Kristina; Polonsky, Tamar; Van Horn, Linda (2020-01-21). "Dietary cholesterol and cardiovascular hazard: A scientific discipline informational from the American Heart Clan". Circulation. 141 (3): e39–e53. doi:10.1161/cir.0000000000000743. ISSN 0009-7322. PMID 31838890.
  6. ^ Campos, Hannia (1992). "LDL Particle Size Distribution". Arteriosclerosis, Thrombosis, and Vascular Biological science. 12 (12): 1410–1419. doi:10.1161/01.ATV.12.12.1410. PMID 1450174.
  7. ^ Kumar V, Butcher SJ, Katrina O, Engelhardt P, Heikkonen J, Kaski 1000, Ala-Korpela M, Kovanen PT (May 2011). "3-Dimensional cryoEM Reconstruction of Native LDL Particles to 16Å Resolution at Physiological Body Temperature". PLOS I. 6 (5): e18841. Bibcode:2011PLoSO...618841K. doi:10.1371/journal.pone.0018841. PMC3090388. PMID 21573056.
  8. ^ Zhang, Da-Wei; Garuti, Rita; Tang, Wan-Jin; Cohen, Jonathan C.; Hobbs, Helen H. (2008-09-02). "Structural requirements for PCSK9-mediated degradation of the depression-density lipoprotein receptor". Proceedings of the National University of Sciences of the United states of america of America. 105 (35): 13045–13050. Bibcode:2008PNAS..10513045Z. doi:10.1073/pnas.0806312105. ISSN 0027-8424. PMC2526098. PMID 18753623.
  9. ^ Santulli G, Jankauskas SS, Gambardella J (May 2021). "Inclisiran: a new milestone on the PCSK9 road to tackle cardiovascular risk". Eur Centre J Cardiovasc Pharmacother. 7 (3): e11–e12. doi:10.1093/ehjcvp/pvab014. PMID 33655296.
  10. ^ Peterson MM, Mack JL, Hall PR, et al. (Dec 2008). "Apolipoprotein B Is an innate bulwark against invasive Staphylococcus aureus infection". Cell Host & Microbe. four (6): 555–66. doi:10.1016/j.chom.2008.ten.001. PMC2639768. PMID 19064256.
  11. ^ a b Ivanova EA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN (2017). "Pocket-size Dense Low-Density Lipoprotein every bit Biomarker for Atherosclerotic Diseases". Oxidative Medicine and Cellular Longevity. 2017 (10): 1273042. doi:10.1155/2017/1273042. PMC5441126. PMID 28572872.
  12. ^ Bhalodkar, Narendra C.; Blum, Steve; Rana, Thakor; Kitchappa, Radha; Bhalodkar, Ami Northward.; Enas, Enas A. (1 May 2005). "Comparison of high-density and low-density lipoprotein cholesterol subclasses and sizes in Asian Indian women with Caucasian women from the framingham offspring study". Clin Cardiol. 28 (5): 247–251. doi:10.1002/clc.4960280510. PMC6654695. PMID 15971461.
  13. ^ "No association between 'bad cholesterol' and elderly deaths: Systematic review of studies of over 68,000 elderly people also raises questions about the benefits of statin drug treatments". sciencedaily.com.
  14. ^ Superko HR, Nejedly M, Garrett B (2002). "Small LDL and its clinical importance as a new CAD risk gene: a female case study". Progress in Cardiovascular Nursing. 17 (4): 167–73. doi:10.1111/j.0889-7204.2002.01453.x. PMID 12417832.
  15. ^ a b Warnick GR, Knopp RH, Fitzpatrick V, Branson L (Jan 1990). "Estimating depression-density lipoprotein cholesterol past the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints". Clinical Chemistry. 36 (1): 15–ix. doi:ten.1093/clinchem/36.1.15. PMID 2297909. Archived from the original on 2019-09-12. Retrieved 2009-11-02 .
  16. ^ Otvos J (June 1999). "Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy". Clin Cardiol. 22 (6 Suppl): II21–seven. doi:10.1002/clc.4960221405. PMC6655988. PMID 10376193.
  17. ^ Staprans, I.; Rapp, J. H.; Pan, 10. Yard.; Feingold, G. R. (1996). "Oxidized lipids in the diet are incorporated by the liver into very low density lipoprotein in rats". Journal of Lipid Research. 37 (two): 420–30. doi:10.1016/S0022-2275(xx)37628-8. PMID 9026539.
  18. ^ a b Ahotupa, Markku (2017). "Oxidized lipoprotein lipids and atherosclerosis". Free Radical Research. 51 (4): 439–447. doi:ten.1080/10715762.2017.1319944. PMID 28412863. S2CID 3397099.
  19. ^ a b Stocker, Roland; Keaney, John F. (2004). "Function of Oxidative Modifications in Atherosclerosis". Physiological Reviews. 84 (4): 1381–1478. doi:10.1152/physrev.00047.2003. PMID 15383655.
  20. ^ Birukov, Chiliad. 1000. (2006). "Oxidized lipids: The ii faces of vascular inflammation". Electric current Atherosclerosis Reports. eight (3): 223–31. doi:10.1007/s11883-006-0077-x. PMID 16640959. S2CID 7852910.
  21. ^ Shao, Baohai; Heinecke, Jay West. (2009). "HDL, lipid peroxidation, and atherosclerosis". Journal of Lipid Research. l (4): 599–601. doi:10.1194/jlr.E900001-JLR200. PMC2656652. PMID 19141435.
  22. ^ John D. Brunzell, MD, FACP, Michael Davidson, Md, FACC, Curt D. Furberg, MD, PhD, Ronald B. Goldberg, MD, Barbara V. Howard, PhD, James H. Stein, Doctor, FACC, FACP and Joseph L. Witztum, MD Lipoprotein Management in Patients With Cardiometabolic Risk, J Am Coll Cardiol, 2008; 51:1512-1524. [1] Archived 2012-02-27 at the Wayback Car
  23. ^ Friedewald WT, Levy RI, Fredrickson DS (June 1972). "Interpretation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge". Clinical Chemistry. eighteen (6): 499–502. doi:10.1093/clinchem/eighteen.six.499. PMID 4337382. Archived from the original on 2019-09-12. Retrieved 2008-05-05 .
  24. ^ Sniderman AD, Bare D, Zakarian R, Bergeron J, Frohlich J (Oct 2003). "Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula". Clinical Biochemistry. 36 (7): 499–504. doi:x.1016/S0009-9120(03)00117-half dozen. PMID 14563441.
  25. ^ http://world wide web.liposcience.com/userfiles/content/files/weightofevidence.pdf [ permanent dead link ]
  26. ^ "Cholesterol Levels". American Heart Association. Retrieved 2009-11-14 .
  27. ^ "What Do My Cholesterol Levels Mean?" (PDF). American Heart Association. September 2007. Retrieved 2009-11-xiv .
  28. ^ "Tertiary Report of the National Cholesterol Instruction Program (NCEP) Expert Console on Detection, Evaluation, and Handling of Loftier Blood Cholesterol in Adults (Developed Treatment Panel Three) Executive Summary" (PDF). National Heart, Lung, and Claret Found (NHLBI). National Institutes of Health. May 2001.
  29. ^ Shepherd J, Cobbe SM, Ford I, et al. (November 1995). "Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. Westward of Scotland Coronary Prevention Study Group". The New England Journal of Medicine. 333 (xx): 1301–7. doi:ten.1056/NEJM199511163332001. PMID 7566020.
  30. ^ William E. Boden, M.D.; et al. (Apr 2007). "Optimal Medical Therapy with or without PCI for Stable Coronary Disease". The New England Journal of Medicine. 356 (xv): 1503–1516. doi:10.1056/NEJMoa070829. PMID 17387127.
  31. ^ Hayward, Rodney A. (iii October 2006). "Narrative Review: Lack of Show for Recommended Depression-Density Lipoprotein Handling Targets: A Solvable Problem". Ann Intern Med. 145 (7): 520–30. doi:10.7326/0003-4819-145-seven-200610030-00010. PMID 17015870.
  32. ^ "The straight dope on cholesterol – Function VI - The Eating Academy - Peter Attia, Thousand.D." 30 May 2012. Archived from the original on 6 May 2016. Retrieved 24 April 2016.
  33. ^ "Google".
  34. ^ Wang, Y Richard; G Caleb Alexander; David O Meltzer (December 2005). "Lack of Result of Guideline Changes on LDL Cholesterol Reporting and Command for Diabetes Visits in the U.Due south., 1995–2004". Diabetes Care. 28 (12): 2942–2944. doi:10.2337/diacare.28.12.2942. PMID 16306559. Retrieved 2011-11-eleven .
  35. ^ Peter P. Toth; Michael Grabner; Rajeshwari S. Punekar; Ralph A. Quimbo; Mark J. Cziraky; Terry A. Jacobson (Baronial 2014). "Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets". Atherosclerosis. 235 (two): 585–591. doi:10.1016/j.atherosclerosis.2014.05.914. PMID 24956532.
  36. ^ Krauss RM (August 2010). "Lipoprotein subfractions and cardiovascular illness risk". Current Opinion in Lipidology. 21 (4): 305–11. doi:10.1097/MOL.0b013e32833b7756. PMID 20531184. S2CID 1775446.
  37. ^ Brunzell, John D.; Davidson, Michael; Furberg, Curt D.; Goldberg, Ronald B.; Howard, Barbara V.; Stein, James H.; Witztum, Joseph Fifty. (15 April 2008). "Lipoprotein Management in Patients With Cardiometabolic Chance". J Am Coll Cardiol. 51 (xv): 1512–1524. doi:10.1016/j.jacc.2008.02.034. PMID 18402913.
  38. ^ "Google".
  39. ^ "MESA - Multi-Indigenous Study of Atherosclerosis".
  40. ^ "Management of Blood Cholesterol in Adults: Systematic Evidence Review from the Cholesterol Expert Panel | National Heart, Lung, and Blood Found (NHLBI)". Archived from the original on 2014-11-25. Retrieved 2014-11-16 .
  41. ^ "Archived copy" (PDF). Archived from the original (PDF) on 2016-03-03. Retrieved 2014-11-16 . {{cite web}}: CS1 maint: archived re-create equally title (link)
  42. ^ a b c d east f g h Consumer Reports; Drug Effectiveness Review Project (March 2013), "Evaluating statin drugs to treat High Cholesterol and Eye Disease: Comparison Effectiveness, Safety, and Cost" (PDF), Best Buy Drugs, Consumer Reports, p. ix, retrieved 27 March 2013 , which cites
    • The states Department of Health and Human Services; National Eye, Lung, and Blood Constitute; National Institutes of Health (June 2005). "NHLBI, High Blood Cholesterol: What Y'all Need to Know". nhlbi.nih.gov. Archived from the original on 2013-04-01. Retrieved 27 March 2013. {{cite web}}: CS1 maint: multiple names: authors list (link)
  43. ^ Inquiry, Center for Drug Evaluation and. "Drug Safety Information for Heathcare [sic] Professionals - Follow-upwards to the Jan 25, 2008 Early Advice about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed equally Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor)". Nutrient and Drug Administration.
  44. ^ Meyers CD, Kamanna VS, Kashyap ML (Dec 2004). "Niacin therapy in atherosclerosis". Current Stance in Lipidology. xv (6): 659–65. doi:10.1097/00041433-200412000-00006. PMID 15529025.
  45. ^ Soudijn W, van Wijngaarden I, Ijzerman AP (May 2007). "Nicotinic acid receptor subtypes and their ligands". Medicinal Research Reviews. 27 (3): 417–33. doi:10.1002/med.20102. PMID 17238156. S2CID 20876888.
  46. ^ "WHO cooperative trial on principal prevention of ischemic centre disease with clofibrate to lower serum cholesterol: last mortality follow-upwards. Report of the Committee of Master Investigators". Lancet. ii (8403): 600–iv. September 1984. doi:10.1016/s0140-6736(84)90595-6. PMID 6147641. S2CID 2473318.
  47. ^ http://world wide web.rxabbott.com/pdf/trilipix_pi.pdf
  48. ^ Song, B.L.; DeBose-Boyd, R.A. (2006). "Insig-Dependent Ubiquitination and Degradation of three-Hydroxy-iii-Methylglutaryl Coenzyme A Reductase Stimulated by Delta- and Gamma-Tocotrienols". J. Biol. Chem. 281 (35): 25054–25601. doi:10.1074/jbc.M605575200. PMID 16831864.
  49. ^ European Nutrient Safety Potency, Periodical (2010). "Scientific opinion on the substantiation of health claims related to plant sterols and plant stanols and maintenance of normal blood cholesterol concentrations".
  50. ^ Genser, B.; Silbernagel, Thou.; De Backer, G.; Bruckert, E.; Carmena, R.; Chapman, One thousand.J.; Deanfield, J.; Descamps, O.South.; Rietzschel, Due east.R.; Dias, K.C.; März, W. (2012). "Plant sterols and cardiovascular affliction: A systematic review and meta-analysis". European Middle Periodical. 33 (4): 444–451. doi:10.1093/eurheartj/ehr441. PMC3279314. PMID 22334625.
  51. ^ Demonty, I.; Ras, R.T.; van der Knaap, H.C.; Duchateau, G.S.; Meijer, L.; Zock, P.Fifty.; Geleijnse, J.One thousand.; Trautwein, E.A. (Feb 2009). "Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake". The Periodical of Nutrition. 139 (2): 271–84. doi:10.3945/jn.108.095125. PMID 19091798.
  52. ^ "Scientists Gene-Hacked Monkeys to Fix Their Cholesterol". Futurism . Retrieved 13 June 2021.
  53. ^ Musunuru, Kiran; et al. (May 2021). "In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates". Nature. 593 (7859): 429–434. Bibcode:2021Natur.593..429M. doi:10.1038/s41586-021-03534-y. ISSN 1476-4687. PMID 34012082. S2CID 234790939. Retrieved 13 June 2021.

External links [edit]

  • Fat (LDL) Deposition: PMAP The Proteolysis Map-animation
  • Adult Treatment Panel 3 Full Report
  • ATP III Update 2004
  • O'Keefe JH, Cordain L, Harris WH, Moe RM, Vogel R (June 2004). "Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal". Periodical of the American Higher of Cardiology. 43 (11): 2142–6. doi:x.1016/j.jacc.2004.03.046. PMID 15172426.

bradleyhiplace.blogspot.com

Source: https://en.wikipedia.org/wiki/Low-density_lipoprotein

0 Response to "Ldl Cholesterol Reading of 76 in 77 Year Old Male"

Post a Comment

Subscribe to: Post Comments (Atom)

Iklan Atas Artikel

Iklan Tengah Artikel 1

Iklan Tengah Artikel 2

Iklan Bawah Artikel